Homburger advises Windward Bio on its USD 165 m Series B Financing

On May 4, 2026, Windward Bio Group AG, a private, clinical-stage biotechnology company committed to improving outcomes for people living with serious immunological diseases, announced an upsized USD 165 m crossover financing led by OrbiMed, with participation from existing Series A investors including Novo Holdings, Blue Owl Healthcare Opportunities, SR One, Omega Funds, RTW Investments, Qiming Venture Partners, Quan Capital, and Pivotal bioVenture Partners. The financing also included new investors RA Capital Management, Janus Henderson Investors, Sanofi Ventures, and Harbour BioMed.

The Homburger team advising Windward Bio includes Margrit Marti, Andreas Müller, Lucas Forrer, Anina Preusker and Géraldine Bär (all Corporate / M&A) as well as Stefan Oesterhelt and Juliette Buob (both Tax).